Focused On-demand Library for DnaJ homolog subfamily C member 27

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NZQ0

UPID:

DJC27_HUMAN

Alternative names:

Rab and DnaJ domain-containing protein

Alternative UPACC:

Q9NZQ0; Q5JV88; Q86Y24

Background:

DnaJ homolog subfamily C member 27, also known as Rab and DnaJ domain-containing protein, plays a pivotal role in cellular processes through its GTPase activity. It activates the MEK/ERK pathway, leading to cell transformation when overexpressed. This protein may also serve as a nuclear scaffold for MAPK1, enhancing ERK1/ERK2 signaling by association with MAPK1 nuclear export signal.

Therapeutic significance:

Understanding the role of DnaJ homolog subfamily C member 27 could open doors to potential therapeutic strategies. Its involvement in the MEK/ERK pathway and cell transformation highlights its significance in cellular signaling and disease mechanisms.